These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 35057104)

  • 1. Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention.
    Ruzic D; Djoković N; Srdić-Rajić T; Echeverria C; Nikolic K; Santibanez JF
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
    Mamdani H; Jalal SI
    Front Cell Dev Biol; 2020; 8():582370. PubMed ID: 33163495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.
    Li G; Tian Y; Zhu WG
    Front Cell Dev Biol; 2020; 8():576946. PubMed ID: 33117804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects: histone deacetylase inhibitors.
    Dokmanovic M; Marks PA
    J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy.
    Verza FA; Das U; Fachin AL; Dimmock JR; Marins M
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32585896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease.
    Kulka LAM; Fangmann PV; Panfilova D; Olzscha H
    Front Cell Dev Biol; 2020; 8():425. PubMed ID: 32582706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma.
    Phimmachanh M; Han JZR; O'Donnell YEI; Latham SL; Croucher DR
    Front Cell Dev Biol; 2020; 8():578770. PubMed ID: 33117806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Histone Deacetylases in Diseases: Where Are We?
    Benedetti R; Conte M; Altucci L
    Antioxid Redox Signal; 2015 Jul; 23(1):99-126. PubMed ID: 24382114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
    Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
    Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase modulators provided by Mother Nature.
    Seidel C; Schnekenburger M; Dicato M; Diederich M
    Genes Nutr; 2012 Jul; 7(3):357-67. PubMed ID: 22328271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations?
    Garmpis N; Damaskos C; Garmpi A; Dimitroulis D; Spartalis E; Margonis GA; Schizas D; Deskou I; Doula C; Magkouti E; Andreatos N; Antoniou EA; Nonni A; Kontzoglou K; Mantas D
    Anticancer Res; 2017 Oct; 37(10):5355-5362. PubMed ID: 28982843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53.
    Mrakovcic M; Bohner L; Hanisch M; Fröhlich LF
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.
    Jenke R; Reßing N; Hansen FK; Aigner A; Büch T
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone Deacetylases and their Inhibitors in Cancer Epigenetics.
    Hassell KN
    Diseases; 2019 Nov; 7(4):. PubMed ID: 31683808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting histone deacetylases for cancer therapy: Trends and challenges.
    Liang T; Wang F; Elhassan RM; Cheng Y; Tang X; Chen W; Fang H; Hou X
    Acta Pharm Sin B; 2023 Jun; 13(6):2425-2463. PubMed ID: 37425042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
    Lauffer BE; Mintzer R; Fong R; Mukund S; Tam C; Zilberleyb I; Flicke B; Ritscher A; Fedorowicz G; Vallero R; Ortwine DF; Gunzner J; Modrusan Z; Neumann L; Koth CM; Lupardus PJ; Kaminker JS; Heise CE; Steiner P
    J Biol Chem; 2013 Sep; 288(37):26926-43. PubMed ID: 23897821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
    Qiu X; Zhu L; Wang H; Tan Y; Yang Z; Yang L; Wan L
    Bioorg Med Chem; 2021 Dec; 52():116510. PubMed ID: 34826681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing histone deacetylase inhibitors as anti-cancer therapeutics.
    Venugopal B; Evans TR
    Curr Med Chem; 2011; 18(11):1658-71. PubMed ID: 21428881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural Agents-Mediated Targeting of Histone Deacetylases.
    Farooqi AA; Naqvi SK; Perk AA; Yanar O; Tabassum S; Ahmad MS; Mansoor Q; Ashry MS; Ismail M; Naoum GE; Arafat WO
    Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):31-44. PubMed ID: 28852775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.